Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 5:09 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 2,507 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Sequence Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug-Drug Interaction Study of Ketoconazole, Rifampicin and Ritonavir-Boosted Atazanavir With Single-Dose RO5093151 in Healthy Volunteers

NCT01591850
View directory record Official record
Conditions
Healthy Volunteer
Interventions
RO5093151, atazanavir, ketoconazole, rifampicin, ritonavir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Merritt Island, Florida
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Nov 2, 2026, 5:09 AM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

Abuse Liability for Five Modern Oral Nicotine Products

NCT07132814
View directory record Official record
Conditions
Smoking, Smoking Behaviors, Tobacco Use, Tobacco Smoking
Interventions
Product A, Product B, Product C, Product D, Product E, Product F, Product N
Other
Lead sponsor
RAI Services Company
Industry
Eligibility
21 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Nov 2, 2026, 5:09 AM EST
Terminated Not applicable Interventional

Yoga Intervention in Head and Neck Cancer Patients Undergoing Concurrent Chemo-Radiation

NCT04146779
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Yoga Video, Posture and Strengthening Video, Relaxation Video, Breath Work Video, Satisfaction Survey, Guided Yoga Session, Written Yoga Instructions
Behavioral
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
21 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Nov 2, 2026, 5:09 AM EST
Terminated Not applicable Interventional Results available

Individualized Repetitive Transcranial Magnetic Stimulation for Auditory Verbal Hallucinations

NCT05319080
View directory record Official record
Conditions
Schizophrenia and Related Disorders
Interventions
Repetitive Transcranial Magnetic Stimulation (rTMS)
Device
Lead sponsor
Columbia University
Other
Eligibility
22 Years to 55 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Nov 2, 2026, 5:09 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence Study Between 400 mg LX4211 Tablets and 2 X 200 mg LX4211 Tablets

NCT02373046
View directory record Official record
Conditions
Healthy
Interventions
LX4211
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2015
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 2, 2015 · Synced Nov 2, 2026, 5:09 AM EST
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Acceptability Study of Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet and Rectally-Applied Tenofovir Reduced-Glycerin 1% Gel

NCT01687218
View directory record Official record
Conditions
HIV
Interventions
Oral FTC/TDF (Daily Emtricitabine/Tenofovir Disoproxil fumarate Tablet), Rectal Daily TFV RG 1% gel (Rectally applied Tenofovir Reduced Glycerin 1% Gel), Rectal RAI-associated TFV RG 1% gel (Receptive Anal Intercourse Associated rectally applied Tenofovir Reduced Glycerin 1% Gel)
Drug
Lead sponsor
CONRAD
Other
Eligibility
18 Years and older · Male only
Enrollment
195 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
3
States / cities
San Francisco, California • Boston, Massachusetts • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 24, 2021 · Synced Nov 2, 2026, 5:09 AM EST
Terminated Phase 1 Interventional

Study of RO7515629 in Participants With HLA-G Positive Solid Tumors

NCT05769959
View directory record Official record
Conditions
Renal Cell Carcinoma, Non-small Cell Lung Cancer, Pancreatic Adenocarcinoma, Colorectal Cancer, Ovarian Neoplasms
Interventions
RO7515629, tocilizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Denver, Colorado • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 9, 2024 · Synced Nov 2, 2026, 5:09 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Drug Interactions Between Danicopan and Cyclosporine, Tacrolimus, Antacids, and Omeprazole in Healthy Adults

NCT05109390
View directory record Official record
Conditions
Healthy
Interventions
Danicopan, Cyclosporine, Tacrolimus, Calcium Carbonate, Aluminum/Magnesium Hydroxide/Simethicone, Omeprazole
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 5, 2021 · Synced Nov 2, 2026, 5:09 AM EST
Completed Phase 2 Interventional

A Study to Assess the Efficacy and Safety of Lorundrostat in Participants With Obstructive Sleep Apnea and Hypertension

NCT06785454
View directory record Official record
Conditions
Obstructive Sleep Apnea, Hypertension
Interventions
Lorundrostat, Placebo
Drug
Lead sponsor
Mineralys Therapeutics Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
27
States / cities
Tuscaloosa, Alabama • Chandler, Arizona • Little Rock, Arkansas + 24 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Nov 2, 2026, 5:09 AM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Pilot Project Exploring the Impact of Whole Genome Sequencing in Healthcare

NCT01736566
View directory record Official record
Conditions
Healthy Adults (Full Study and Extension Phase), Hypertrophic Cardiomyopathy or Dilated Cardiomyopathy
Interventions
Family History + Whole Genome Sequencing, Family History Only
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 90 Years
Enrollment
213 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 27, 2024 · Synced Nov 2, 2026, 5:09 AM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Estrogen and Serotonin on Changing Brain Chemistry

NCT01208324
View directory record Official record
Conditions
Menopause
Interventions
estrogen patch, Amino acids, Placebo Patch, Placebo pills
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
48 Years to 60 Years · Female only
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 2, 2021 · Synced Nov 2, 2026, 5:09 AM EST
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Meditation and Yogic Breathing-driven Modulation of Neurofluid Coupling and Brain Clearance

NCT07903688
View directory record Official record
Conditions
Healthy
Interventions
Nadi Shuddhi, Shoonya Meditation
Behavioral
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
25 Years to 60 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Nov 2, 2026, 5:09 AM EST
Completed Phase 3 Interventional Results available

Docetaxel in Breast Cancer

NCT00312208
View directory record Official record
Conditions
Breast Cancer
Interventions
Docetaxel,doxorubicin, cyclophosphamide
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 70 Years · Female only
Enrollment
3,299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2013
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 30, 2013 · Synced Nov 2, 2026, 5:09 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Pharmacokinetics (PK) Study of Natrunix in Healthy Volunteers

NCT05099510
View directory record Official record
Conditions
Pharmacokinetics
Interventions
Natrunix, Placebo
Biological
Lead sponsor
XBiotech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Nov 2, 2026, 5:09 AM EST
Completed Phase 3 Interventional Results available

Comparison of CHS-1420 Versus Humira in Subjects With Chronic Plaque Psoriasis

NCT02489227
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
CHS-1420, Adalimumab
Drug
Lead sponsor
Coherus Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
545 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
28
States / cities
Phoenix, Arizona • Encino, California • Sacramento, California + 23 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2020 · Synced Nov 2, 2026, 5:09 AM EST
Terminated Phase 1 Interventional Accepts healthy volunteers

Hookah Smoking, Carbon Monoxide, and Coronary Endothelial Function

NCT03166787
View directory record Official record
Conditions
Smoking, Endothelial Dysfunction
Interventions
Charcoal hookah, E-coal hookah, Cigarette, Carbon Monoxide inhalation, Room Air inhalation, vitamin C, tadalafil
Other · Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
21 Years to 49 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 9, 2021 · Synced Nov 2, 2026, 5:09 AM EST
Completed Phase 1Phase 2 Interventional Results available

Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies

NCT03363893
View directory record Official record
Conditions
Advanced Solid Malignancies
Interventions
CT7001, Fulvestrant
Drug
Lead sponsor
Carrick Therapeutics Limited
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
12
States / cities
Tucson, Arizona • Beverly Hills, California • Tampa, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Nov 2, 2026, 5:09 AM EST
Completed Phase 3 Interventional

A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer

NCT04229004
View directory record Official record
Conditions
Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma
Interventions
Gemcitabine combined with nab-paclitaxel, Dose -mFOLFIRINOX, Dose - Pamrevlumab combined with gemcitabine and nab-paclitaxel, Dose- Canakinumab and Spartalizumab combined with nab-paclitaxel and gemcitabine, Drug: Dose -SM-88
Drug
Lead sponsor
Pancreatic Cancer Action Network
Other
Eligibility
18 Years and older
Enrollment
502 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
25
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2025 · Synced Nov 2, 2026, 5:09 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalency Study of Oxymorphone Hydrochloride 10 mg Tablets Under Fasted Conditions

NCT01210638
View directory record Official record
Conditions
Pain
Interventions
Oxymorphone
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Nov 2, 2026, 5:09 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Food Effect and Relative Bioavailability Study of Rilzabrutinib in Healthy Participants

NCT06342700
View directory record Official record
Conditions
Autoimmune Disorder, Healthy Volunteers
Interventions
Rilzabrutinib crystalline form, Rilzabrutinib amorphous form
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced Nov 2, 2026, 5:09 AM EST
Withdrawn Phase 1 Interventional Accepts healthy volunteers

A Drug Interaction Study Evaluating Plasma GSK2248761 and GSK1349572 Pharmacokinetics in Healthy Adult Subjects.

NCT01283100
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus I
Interventions
GSK1349572, GSK2248761
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Dec 24, 2014 · Synced Nov 2, 2026, 5:09 AM EST
Recruiting Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Safety and Effects of Psychoactive Substances in People With Past Opioid Use

NCT07218549
View directory record Official record
Conditions
Opioid Use, Substance Use Disorders, Opioid Analgesia
Interventions
Placebo, Oxycodone HCl, Kratom 8g, Kratom 12g, Kratom 16g, Kratom 4g
Drug
Lead sponsor
Christopher D. Verrico
Other
Eligibility
18 Years to 55 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Nov 2, 2026, 5:09 AM EST
Recruiting No phase listed Observational Accepts healthy volunteers

Utilizing Long-read Sequencing to Investigate the EGFR Landscape of EGFR Positive Lung Cancer Patients

NCT06659458
View directory record Official record
Conditions
Lung Cancer - Non Small Cell, EGFR Exon 19 Deletion Mutation
Interventions
blood draw, Gene sequencing
Other
Lead sponsor
Our Lady of the Lake Hospital
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Mar 20, 2025 · Synced Nov 2, 2026, 5:09 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Relative Bioavailability Study of UCB0022 Tablets in Healthy Participants

NCT07220551
View directory record Official record
Conditions
Healthy Volunteers
Interventions
UCB0022
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Nov 2, 2026, 5:09 AM EST